Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cloudbreak PharmaHKSE:02592 +1.64%11 Pretax Margin % is % as of Dec. 2025. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Cloudbreak Pharma ranks worse than 105932.1% on this metric.
The historical rank and industry rank for Cloudbreak Pharma's Pretax Margin % or its related term are showing as below:
HKSE:02592's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.365 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Cloudbreak Pharma Pretax Margin % Related Terms
Cloudbreak Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Cloudbreak Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02592 vs VRTX, REGN, RVMD: Pretax Margin % Comparison
For the Biotechnology subindustry, Cloudbreak Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cloudbreak Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cloudbreak Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Cloudbreak Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cloudbreak Pharma (HKSE:02592) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cloudbreak Pharma and its competitors. According to the industry distribution chart, Cloudbreak Pharma ranks #999999 out of 944 companies in the Biotechnology industry.
Is Cloudbreak Pharma's Pretax Margin % too high?
Cloudbreak Pharma's current Pretax Margin % is %. Based on the distribution chart, Cloudbreak Pharma ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cloudbreak Pharma ranks #999999 out of 944 companies for Pretax Margin %. This places Cloudbreak Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cloudbreak Pharma and its competitors. Cloudbreak Pharma's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Pretax Margin % of %. The current Pretax Margin % is %. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score
Get the complete analysis for HKSE:02592
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02592 has been successfully added to your 
